Importantly, this implies that EPHB6 may be used as a new biomarker for selecting TNBC tumours sensitive to DR5 activation and that DR5 agonists could produce better results if used selectively to treat EPHB6-positive tumours. This evidence concerns the gene TNFRSF10B and neoplasm.